[Dexmedetomidine. Pharmacokinetics and Pharmacodynamics]
Overview
Affiliations
Dexmedetomidine is a highly selective, potent α₂-adrenoceptor agonist which was approved in 2011 by the European Medicines Agency for sedation of patients in intensive care units (ICU). Dexmedetomidine exhibits sedative as well as analgesic and anxiolytic effects. Recent studies suggest that dexmedetomidine may be an alternative to midazolam in long-term ICU sedation. This review summarizes the pharmacokinetics and pharmacodynamics of dexmedetomidine particularly in ICU patients and with special regard to covariate effects. Although dexmedetomidine is currently approved only for use in adults the pharmacokinetics and pharmacodynamics in children will also be addressed as there are numerous studies on this off-label use.
Jia Z, Chen Y, Gao T, Yuan Y, Zheng Y, Xie Y Front Pharmacol. 2023; 14:1131812.
PMID: 36762101 PMC: 9905252. DOI: 10.3389/fphar.2023.1131812.
Recent Advances in the Clinical Value and Potential of Dexmedetomidine.
Liu X, Li Y, Kang L, Wang Q J Inflamm Res. 2022; 14:7507-7527.
PMID: 35002284 PMC: 8724687. DOI: 10.2147/JIR.S346089.
Zhai W, Yang L, Sun P, Li Y, Han J, Wang G Exp Ther Med. 2020; 20(6):250.
PMID: 33178348 PMC: 7651881. DOI: 10.3892/etm.2020.9380.
Magazine R, Venkatachala S, Goneppanavar U, Surendra V, Guddattu V, Chogtu B Indian J Pharmacol. 2020; 52(1):23-30.
PMID: 32201443 PMC: 7074428. DOI: 10.4103/ijp.IJP_287_19.
Tu Y, Gao F Medicine (Baltimore). 2018; 96(51):e9369.
PMID: 29390531 PMC: 5758233. DOI: 10.1097/MD.0000000000009369.